These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33396700)

  • 61. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE; Merino JL; Barrios V
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study.
    Cappannoli L; Laborante R; Galli M; Canonico F; Ciliberti G; Restivo A; Princi G; Arcudi A; Sabatelli M; De Cristofaro R; Crea F; D'Amario D
    Front Cardiovasc Med; 2022; 9():1052053. PubMed ID: 36620634
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.
    Rago A; Papa AA; Attena E; Parisi V; Golino P; Nigro G; Russo V
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1003-1007. PubMed ID: 32946035
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Edoxaban: an update on the new oral direct factor Xa inhibitor.
    Bounameaux H; Camm AJ
    Drugs; 2014 Jul; 74(11):1209-31. PubMed ID: 25034361
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
    Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
    Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
    Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
    JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk of hemorrhagic transformation with early use of direct oral anticoagulants after acute ischemic stroke: A pooled analysis of prospective studies and randomized trials.
    Alrohimi A; Rose DZ; Burgin WS; Renati S; Hilker NC; Deng W; Oliveira GH; Beckie TM; Labovitz AJ; Fradley MG; Tran N; Gioia LC; Kate M; Ng K; Dowlatshahi D; Field TS; Coutts SB; Siddiqui M; Hill MD; Miller J; Jickling G; Shuaib A; Buck B; Sharma M; Butcher KS
    Int J Stroke; 2023 Aug; 18(7):864-872. PubMed ID: 36907985
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
    Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs).
    Nemola G; Russi A; Cozzani G; Leo G; Vetrugno L; Sparasci FM; Parlati AL; Della Bella P; Montorfano M; Tresoldi M; Salerno A; Cera M; Mattiello P; Comi G; Maisano F; Zangrillo A; Gaspardone C; Melillo F; Margonato A; Godino C;
    Am J Cardiol; 2023 Nov; 206():125-131. PubMed ID: 37703678
    [TBL] [Abstract][Full Text] [Related]  

  • 74. New Oral Anticoagulant Versus Vitamin K Antagonists for Thoracoscopic Ablation in Patients With Persistent Atrial Fibrillation: A Randomized Controlled Trial.
    Lee Y; Jeong DS; Ahn J; Park KM; Park SJ; Kim JS; On YK
    Semin Thorac Cardiovasc Surg; 2023; 35(2):268-274. PubMed ID: 34879226
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation.
    Zhou LY; Yang SF; Zhang Z; Zhang C; Shen L; Gu ZC; Zuo XC
    Front Physiol; 2018; 9():1644. PubMed ID: 30524307
    [No Abstract]   [Full Text] [Related]  

  • 77. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia　- One-Year Data From the Global ETNA-AF Program.
    Choi JI; Kiatchoosakun S; Jiampo P; Tse HF; Soo YOY; Wang CC; Lee CH; Pecen L; Unverdorben M; De Caterina R; Kirchhof P
    Circ Rep; 2024 Mar; 6(3):86-93. PubMed ID: 38464984
    [No Abstract]   [Full Text] [Related]  

  • 78. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
    J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation).
    Antonenko K; Paciaroni M; Agnelli G; Falocci N; Becattini C; Marcheselli S; Rueckert C; Pezzini A; Poli L; Padovani A; Csiba L; Szabó L; Sohn SI; Tassinari T; Abdul-Rahim AH; Michel P; Cordier M; Vanacker P; Remillard S; Alberti A; Venti M; Acciarresi M; D'Amore C; Scoditti U; Denti L; Orlandi G; Chiti A; Gialdini G; Bovi P; Carletti M; Rigatelli A; Putaala J; Tatlisumak T; Masotti L; Lorenzini G; Tassi R; Guideri F; Martini G; Tsivgoulis G; Vadikolias K; Papageorgiou SG; Corea F; Sette MD; Ageno W; Lodovici ML; Bono G; Baldi A; D'Anna S; Sacco S; Carolei A; Tiseo C; Imberti D; Zabzuni D; Doronin B; Volodina V; Consoli D; Galati F; Pieroni A; Toni D; Monaco S; Baronello MM; Barlinn K; Pallesen LP; Kepplinger J; Bodechtel U; Gerber J; Deleu D; Melikyan G; Ibrahim F; Akhtar N; Mosconi MG; Lees KR; Caso V
    Eur Stroke J; 2017 Mar; 2(1):46-53. PubMed ID: 30886901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.